Opiant Pharmaceuticals (OPNT) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-38193
Entity Registrant Name	OPIANT PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4744124
Entity Address, Address Line One	233 Wilshire Blvd.
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Santa Monica,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90401
City Area Code	310
Local Phone Number	598-5410
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,167,814
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	OPNT
Security Exchange Name	NASDAQ
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001385508
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 35,375,865	$ 37,853,947
Marketable securities	0	15,014,750
Accounts receivable	41,113	13,327,364
Prepaid and other current assets	3,131,299	2,962,903
Total current assets	38,548,277	69,158,964
Other assets
Property and equipment, net	417,646	78,107
Right of use assets - operating leases	2,739,239	999,567
Patents and patent applications, net	10,598	11,628
Other non-current assets	234,389	179,532
Total assets	41,950,149	70,427,798
Current liabilities
Accounts payable and accrued liabilities	3,113,068	3,369,848
Accrued salaries and wages	1,821,438	201,254
Royalty payable	0	2,920,148
Deferred revenue	0	16,618
Operating leases - current	669,209	337,690
Convertible debt - current	1,436,660	0
Total current liabilities	7,040,375	6,845,558
Long-term liabilities
Operating leases - long term	2,083,548	673,347
Convertible debt, net of unamortized discount	12,324,237	16,069,085
Total liabilities	21,448,160	23,587,990
Stockholders' equity
Common stock; par value $0.001; 200,000,000 shares authorized; 5,164,951 and 4,909,846 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	5,165	4,910
Additional paid-in capital	116,266,243	108,569,988
Accumulated other comprehensive loss	(248,129)	(54,815)
Accumulated deficit	(95,521,290)	(61,680,275)
Total stockholders' equity	20,501,989	46,839,808
Total liabilities and stockholders' equity	$ 41,950,149	$ 70,427,798

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	5,164,951	4,909,846
Common stock, shares outstanding (in shares)	5,164,951	4,909,846

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues
Royalty revenue	$ 0	$ 14,041,006	$ 4,519,505	$ 27,688,713
Grant and contract revenue	173,874	2,298,055	4,018,653	6,296,542
Total revenue	173,874	16,339,061	8,538,158	33,985,255
Operating expenses
General and administrative	3,073,114	3,378,707	11,415,746	8,758,601
Research and development	4,133,982	4,881,398	20,873,449	12,119,088
Sales and marketing	2,596,562	1,059,649	8,088,860	3,080,211
Royalty expense	0	3,058,865	943,269	6,145,057
Total operating expenses	9,803,658	12,378,619	41,321,324	30,102,957
Income (loss) from operations	(9,629,784)	3,960,442	(32,783,166)	3,882,298
Other income (expense)
Interest income	160,114	3,498	227,830	10,334
Interest expense	(390,850)	(547,296)	(1,213,021)	(1,626,273)
Loss on sale of assets	(49,437)	0	(49,437)	0
Gain (loss) on foreign exchange	1,868	455	17,818	(9,899)
Total other income (expense)	(278,305)	(543,343)	(1,016,810)	(1,625,838)
Income (loss) before income taxes	(9,908,089)	3,417,099	(33,799,976)	2,256,460
Income tax (expense)	(8,550)	0	(41,039)	0
Net income (loss)	(9,916,639)	3,417,099	(33,841,015)	2,256,460
Other comprehensive loss:
Foreign currency translation adjustment	(4,979)	(7,974)	(193,314)	81
Comprehensive income (loss)	$ (9,921,618)	$ 3,409,125	$ (34,034,329)	$ 2,256,541
Net income (loss) per share of common stock:
Basic (in dollars per share)	$ (1.93)	$ 0.77	$ (6.66)	$ 0.52
Diluted (in dollars per share)	$ (1.93)	$ 0.56	$ (6.66)	$ 0.41
Weighted average shares outstanding used to compute net income (loss) per share:
Basic (in shares)	5,138,274	4,462,236	5,083,222	4,359,759
Diluted (in shares)	5,138,274	6,065,044	5,083,222	5,565,065

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2020		4,258,105
Beginning balance at Dec. 31, 2020	$ 35,492,242	$ 4,259	$ 100,203,979	$ (64,689,065)	$ (26,931)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		65,962
Exercise of stock options	579,619	$ 66	579,553
Restricted stock issued (in shares)		6,527
Restricted stock issued	0	$ 6	(6)
Stock based compensation	745,620		745,620
Net (loss) income	(2,844,230)			(2,844,230)
Other comprehensive loss - foreign currency translation adjustment	12,501				12,501
Ending balance (in shares) at Mar. 31, 2021		4,330,594
Ending balance at Mar. 31, 2021	33,985,752	$ 4,331	101,529,146	(67,533,295)	(14,430)
Beginning balance (in shares) at Dec. 31, 2020		4,258,105
Beginning balance at Dec. 31, 2020	35,492,242	$ 4,259	100,203,979	(64,689,065)	(26,931)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Debt issuance cost associated with debt conversion	0
Net (loss) income	2,256,460
Other comprehensive loss - foreign currency translation adjustment	81
Ending balance (in shares) at Sep. 30, 2021		4,618,221
Ending balance at Sep. 30, 2021	42,005,357	$ 4,618	104,460,194	(62,432,605)	(26,850)
Beginning balance (in shares) at Mar. 31, 2021		4,330,594
Beginning balance at Mar. 31, 2021	33,985,752	$ 4,331	101,529,146	(67,533,295)	(14,430)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		5,630
Exercise of stock options	36,605	$ 6	36,599
Restricted stock issued (in shares)		13,375
Restricted stock issued	0	$ 13	(13)
Stock based compensation	654,562		654,562
Net (loss) income	1,683,591			1,683,591
Other comprehensive loss - foreign currency translation adjustment	(4,446)				(4,446)
Ending balance (in shares) at Jun. 30, 2021		4,349,599
Ending balance at Jun. 30, 2021	36,356,064	$ 4,350	102,220,294	(65,849,704)	(18,876)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		268,622
Exercise of stock options	1,545,834	$ 268	1,545,566
Stock based compensation	694,334		694,334
Net (loss) income	3,417,099			3,417,099
Other comprehensive loss - foreign currency translation adjustment	(7,974)				(7,974)
Ending balance (in shares) at Sep. 30, 2021		4,618,221
Ending balance at Sep. 30, 2021	$ 42,005,357	$ 4,618	104,460,194	(62,432,605)	(26,850)
Beginning balance (in shares) at Dec. 31, 2021	4,909,846	4,909,846
Beginning balance at Dec. 31, 2021	$ 46,839,808	$ 4,910	108,569,988	(61,680,275)	(54,815)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Return of profit	5,824		5,824
Exercise of stock options (in shares)		7,097
Exercise of stock options	91,634	$ 7	91,627
Restricted stock issued (in shares)		31,746
Restricted stock issued	0	$ 32	(32)
Stock issued from converted debt (in shares)		130,916
Stock issued from converted debt	2,571,200	$ 131	2,571,069
Debt issuance cost associated with debt conversion	(109,399)		(109,399)
Stock based compensation	2,079,159		2,079,159
Net (loss) income	(12,187,830)			(12,187,830)
Other comprehensive loss - foreign currency translation adjustment	(27,150)				(27,150)
Ending balance (in shares) at Mar. 31, 2022		5,079,605
Ending balance at Mar. 31, 2022	$ 39,263,246	$ 5,080	113,208,236	(73,868,105)	(81,965)
Beginning balance (in shares) at Dec. 31, 2021	4,909,846	4,909,846
Beginning balance at Dec. 31, 2021	$ 46,839,808	$ 4,910	108,569,988	(61,680,275)	(54,815)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock issued (in shares)		51,671
Performance stock units issued (in shares)		20,185
Issuance of common stock, net of issuance cost (in shares)		7,097
Debt issuance cost associated with debt conversion	(109,399)
Net (loss) income	(33,841,015)
Other comprehensive loss - foreign currency translation adjustment	$ (193,314)
Ending balance (in shares) at Sep. 30, 2022	5,164,951	5,164,951
Ending balance at Sep. 30, 2022	$ 20,501,989	$ 5,165	116,266,243	(95,521,290)	(248,129)
Beginning balance (in shares) at Mar. 31, 2022		5,079,605
Beginning balance at Mar. 31, 2022	39,263,246	$ 5,080	113,208,236	(73,868,105)	(81,965)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	0
Restricted stock issued (in shares)		15,375
Restricted stock issued	0	$ 15	(15)
Performance stock units issued (in shares)		20,185
Performance stock units issued	0	$ 20	(20)
Issuance of common stock, net of issuance cost (in shares)		7,410
Issuance of common stock, net of issuance cost	135,678	$ 6	135,672
Stock based compensation	2,095,118		2,095,118
Net (loss) income	(11,736,546)			(11,736,546)
Other comprehensive loss - foreign currency translation adjustment	(161,185)				(161,185)
Ending balance (in shares) at Jun. 30, 2022		5,122,575
Ending balance at Jun. 30, 2022	29,596,311	$ 5,121	115,438,991	(85,604,651)	(243,150)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock issued (in shares)		4,550
Restricted stock issued	0	$ 6	(6)
Issuance of common stock, net of issuance cost (in shares)		37,826
Issuance of common stock, net of issuance cost	402,615	$ 38	402,577
Stock based compensation	424,681		424,681
Net (loss) income	(9,916,639)			(9,916,639)
Other comprehensive loss - foreign currency translation adjustment	$ (4,979)				(4,979)
Ending balance (in shares) at Sep. 30, 2022	5,164,951	5,164,951
Ending balance at Sep. 30, 2022	$ 20,501,989	$ 5,165	$ 116,266,243	$ (95,521,290)	$ (248,129)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net income (loss)	$ (33,841,015)	$ 2,256,460
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	28,013	78,701
Amortization of debt discount	153,613	205,177
Loss on sale of fixed assets	49,437	0
Non-cash lease expense	384,916	388,598
Stock based compensation	4,598,958	2,094,516
Change in assets and liabilities:
(Increase) decrease in accounts receivable	13,286,251	(6,514,964)
(Increase) decrease in prepaid expenses	(296,020)	860,631
Increase (decrease) in accounts payable and accrued liabilities	(198,361)	(481,464)
Increase (decrease) in accrued salaries and wages	1,672,129	553,996
Increase (decrease) in lease liabilities	(370,033)	(392,564)
Increase (decrease) in royalty payable	(2,920,148)	1,228,605
Increase (decrease) in deferred revenue	(16,618)	(354,756)
Net cash used in operating activities	(17,468,878)	(77,064)
Cash flows from investing activities
Maturity (purchase) of marketable securities	15,014,750
Maturity (purchase) of marketable securities		(15,044,750)
Purchase of property and equipment	(418,962)	0
Net cash provided by (used in) investing activities	14,595,788	(15,044,750)
Cash flows from financing activities
Proceeds from issuance of common shares	538,293	0
Proceeds from stock option and warrant exercises	97,458	2,162,058
Net cash provided by financing activities	635,751	2,162,058
Effect of foreign currency translation on cash	(240,743)	(6,985)
Net increase (decrease) in cash and cash equivalents	(2,478,082)	(12,966,741)
Cash and cash equivalents, beginning of period	37,853,947	48,251,336
Cash and cash equivalents, end of period	35,375,865	35,284,595
Supplemental disclosure
Interest paid during the period	1,158,940	1,051,508
Income taxes paid during the period	66,924	0
Debt Conversion, Converted Instrument, Amount	2,571,200	0
Supplemental disclosure of non-cash finance transactions
Debt issuance cost associated with debt conversion	109,399	0
Right of use assets obtained in exchange for new lease obligations	2,106,776	1,094,259
Issuance of restricted stock and performance stock units	$ 73	$ 19

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Company Opiant is a specialty pharmaceutical company developing medicines for addiction and drug overdose. The Company developed NARCAN® (naloxone hydrochloride) Nasal Spray (“NARCAN®”), a treatment to reverse opioid overdose. This product was conceived and developed by the Company, licensed to Adapt Pharma Operations Limited (“Adapt”), an Ireland based pharmaceutical company in December 2014 and approved by the U.S. Food and Drug Administration (“FDA”) in November 2015. In October 2018, Emergent BioSolutions, Inc. ("EBS") completed its acquisition of Adapt. The Company's current pipeline includes medicines in development for Opioid Overdose Reversal (“OOR”), Alcohol Use Disorder (“AUD”), and Acute Cannabinoid Overdose (“ACO”). The Company is also pursuing other treatment opportunities within the addiction and drug overdose field. The Company has not had a bankruptcy, receivership or similar proceeding. The Company is required to comply with all regulations, rules and directives of governmental authorities and agencies applicable to the clinical testing and manufacturing and sale of pharmaceutical products.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly the Company's financial position as of September 30, 2022 and December 31, 2021, results of operations for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited, a company incorporated on November 4, 2016 under the England and Wales Companies Act of 2006. Intercompany balances and transactions are eliminated upon consolidation. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K filed with the SEC on March 15, 2022. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of: deferred income tax assets, equity instruments, stock-based compensation, acquired intangibles, and allowances for accounts receivable. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents were approximately $35.4 million and $37.9 million at September 30, 2022 and December 31, 2021, respectively. The Company maintains cash balances at financial institutions insured up to $250 thousand by the Federal Deposit Insurance Corporation. Balances in the UK are insured up to £85 thousand by the Financial Services Compensation Scheme (UK Equivalent). Although the Company’s cash balances exceeded these insured amounts at various times during the nine months ended September 30, 2022, the Company has not experienced any losses on its deposits of cash and cash equivalents for the periods presented. Earnings (Loss) Per Share Basic and diluted earnings (loss) per share is computed by dividing loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period. Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the respective period presented in the Company’s accompanying condensed consolidated financial statements. Fully-diluted earnings (loss) per share is computed similarly to basic income (loss) per share except that the denominator is increased to include the number of Common Stock equivalents (primarily outstanding options and warrants). (in thousands, except per share data) For the Three Months Ended September 30, For the Nine Months Ended September 30, Numerator: 2022 2021 2022 2021 Net Income (loss) $ (9,917) $ 3,417 $ (33,841) $ 2,256 Denominator: Denominator for basic income (loss) per share - weighted average shares 5,138,274 4,462,236 5,083,222 4,359,759 Effect of dilutive securities: Equity incentive plans — 1,602,808 — 1,205,306 Denominator for diluted income (loss) per share 5,138,274 6,065,044 5,083,222 5,565,065 Income (loss) per share - Basic $ (1.93) $0.77 $ (6.66) $ 0.52 Income (loss) per share - Diluted $ (1.93) $0.56 $ (6.66) $ 0.41 The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive. For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Options to purchase common stock 2,745,815 295,550 2,745,815 407,975 Warrants to purchase common stock 278,800 — 278,800 — Unvested restricted stock 268,093 — 268,093 21,425 Unvested performance stock 20,185 — 20,185 — Shares issuable upon conversion of convertible debt 222,332 509,165 222,332 509,165 Total 3,535,225 804,715 3,535,225 938,565 Foreign Currency Translation The functional currency of the Company's wholly-owned subsidiary, Opiant UK is the British Pound, its local currency. Consequently, its assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of Opiant Pharmaceuticals UK Limited (“Opiant UK”), into U.S. dollars, the reporting currency, are excluded from the determination of net loss and are recorded in accumulated other comprehensive loss, a separate component of equity. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, ("FASB"), or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable SecuritiesThe Company invests in debt securities and has the intent and ability to hold until maturity. Therefore, the Company's Securities are classified as held-to-maturity. The Company's debt securities are all U.S. Treasury securities. The investments in debt securities are carried at either amortized cost or fair value. As of September 30, 2022, the Company had no marketable securities. Any debt securities with original maturities of three months or less are classified as cash equivalents.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Accounts Receivable	Accounts Receivable    As of September 30, 2022, the Company had $41 thousand in accounts receivable due from BARDA. As of December 31, 2021, the Company had $13.3 million in accounts receivable, which primarily related to royalty revenue from net sales of NARCAN®.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets    As of September 30, 2022 and December 31, 2021, the Company had prepaid expenses and other current assets of approximately $3.1 million and $3.0 million, respectively. The Company's prepaid expenses are primarily for advance research and development payments, insurance, software licenses, prepaid rent, and other amounts that relate to future periods of service. Other current assets primarily consist of such items as other receivables and security deposits.Other Non-Current AssetsAs of September 30, 2022 and December 31, 2021, the Company had other non-current assets of approximately $234 thousand and $180 thousand, respectively. The Company's non-current prepaid expenses are primarily for deposits.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	Leases On January 1, 2019, the Company adopted a new accounting standard, Topic 842, that amends the guidance for the accounting and reporting of leases. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Company's Condensed Consolidated Balance Sheets. The Company has two operating leases with terms greater than 12 months as of September 30, 2022. In accordance with the guidance of Topic 842, the leases which are classified as operating leases must be included in the Company's Condensed Consolidated Balance Sheets . The Santa Monica operating lease contains an option to renew once for five years, which the Company does not expect to exercise, the other lease does not contain a renewal option. The operating leases do not contain residual value guarantees, do not have variable lease components, or impose significant restrictions or covenants. Right of use assets, "ROU assets", represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments over the respective lease term, with the ROU asset adjusted for deferred rent liability. Lease expense is recognized on a straight line basis over the lease term. As the implicit rate on the leases is not determinable, the Company uses judgement to estimate the incremental borrowing rate which is used as the discount rate to determine the present value of lease payments. The weighted average discount rate used was 8.8% and the weighted average remaining lease term is 4.6 years. The following table summarizes information related to the Company's operating leases and are included in the Company's Balance Sheet as of September 30, 2022. Balance Sheet descriptions September 30, 2022 Assets: (in thousands) Right of use assets - operating leases $ 2,739 Liabilities: Operating leases - current 669 Operating leases - long term 2,084 Total lease liabilities: $ 2,753 The following table summarizes the components of operating lease cost for the three and nine months ended September 30, 2022: Lease costs, (in thousands) Three months ended September 30, 2022 Nine months ended September 30, 2022 Operating expenses lease costs $ 149 $ 395 As of September 30, 2022, future minimum operating leases payments related to the Company’s operating lease liabilities were as follows: (in thousands) September 30, 2022 2022 (three months remaining) $ 179 2023 709 2024 737 2025 780 2026 and thereafter 1,036 Total lease payments 3,441 Less imputed interest (688) Present value of operating lease liabilities $ 2,753

Other Non-Current Assets

Other Non-Current Assets	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Non-Current Assets	Prepaid Expenses and Other Current Assets    As of September 30, 2022 and December 31, 2021, the Company had prepaid expenses and other current assets of approximately $3.1 million and $3.0 million, respectively. The Company's prepaid expenses are primarily for advance research and development payments, insurance, software licenses, prepaid rent, and other amounts that relate to future periods of service. Other current assets primarily consist of such items as other receivables and security deposits.Other Non-Current AssetsAs of September 30, 2022 and December 31, 2021, the Company had other non-current assets of approximately $234 thousand and $180 thousand, respectively. The Company's non-current prepaid expenses are primarily for deposits.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2022
Revenue Recognition [Abstract]
Revenue	Revenue NARCAN® Royalties The Company's primary source of revenue has been from royalty payments received from NARCAN® net sales by EBS. During the three months ended September 30, 2022 the Company did not record any royalty revenue. On August 10, 2022, the Company, delivered a notice (the "Default Notice") to EBS under section 10.3 the Adapt Agreement to put EBS on notice that EBS had breached one or more of its obligations under the Adapt Agreement. On November 14, 2022, the Company entered into an agreement with EBS to settle the Default Notice dated August 10, 2022 and terminate the Company's rights to receive any further payments, including royalties, under the License Agreement (see Note 13). For the nine months ended September 30, 2022, the Company recorded $4.5 million in royalty revenue related to its agreement with EBS, before it was terminated. BARDA Contract On September 19, 2018, the Company entered into a contract with the Biomedical Advanced Research and Development Authority (“BARDA”), which is part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to accelerate the Company’s development of OPTN003, its lead product candidate. OPTN003, nasal nalmefene, is a potent, long-acting opioid antagonist currently in development for the treatment of opioid overdose. The contract provides funding up to approximately $10.8 million and covers activities related to the New Drug Application for OPTN003 with the Food and Drug Administration. BARDA has awarded approximately $10.8 million of the contract as of September 30, 2022. During the three and nine months ended September 30, 2022, the Company recognized revenue of $0.2 million and $4.0 million, respectively related to this contract. Deferred revenue On April 17, 2018, the Company was awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse, ("NIDA"). The grant provided the Company with additional resources for the development of OPNT003. Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. The Company recognized revenues from grants in the period during which the related costs were incurred, provided that the conditions under which the grants were provided had been met and only perfunctory obligations were outstanding. As of March 31, 2022, the Company had received the entire $7.4 million, and all the work related to the grant was complete. During the three and nine months ended September 30, 2022, the Company recognized revenue of $0 and $17 thousand, respectively related to this grant. The following is a summary of the Company’s deferred revenue activity as of September 30, 2022: (in thousands) NIDA Grant Total Balance as of December 31, 2021 $ 17 $ 17 Additions to deferred revenue — — Recognized as revenue (17) (17) Balance as of September 30, 2022 $ — $ —

Royalty Payable

Royalty Payable	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Royalty Payable	Royalty Payable    The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development of its Opioid Overdose Reversal Treatment Product ("OORTP"). In exchange for this funding, the Company agreed to provide investors with interest in the OORTP net profit generated from NARCAN® sales by EBS into perpetuity. As of September 30, 2022, the Company did not record any royalty payable (see Note 13). As of December 31, 2021, the Company recorded a $2.9 million royalty payable.

Debt

Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt As of September 30, 2022 the Company had short and long term debt (net of amortization discount) of $13.8 million. As of December 31, 2021, the Company had long term debt (net of amortization discount) of $16.1 million. There have been no changes to the maturity or other conditions of the debt for the nine months ended September 30, 2022. During the nine months ended September 30, 2022 approximately $2.6 million of debt was converted to Common Stock at a conversion price of $19.64 per share.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity Common Stock During the nine months ended September 30, 2022, the Company issued 7,097 shares of Common Stock as a result of stock option exercises, and received net cash proceeds of approximately $92 thousand. During the nine months ended September 30, 2022, the Company sold 45,236 shares of Common Stock and received net proceeds of $538 thousand after deducting sales commission under its Controlled Equity Offering with Cantor Fitzgerald & Company. During the nine months ended September 30, 2022, the Company issued 51,671 shares of Common Stock for restricted stock units that vested. During the nine months ended September 30, 2022, the Company issued 20,185 shares of Common Stock for performance stock units that vested. Equity Plans On September 8, 2017, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”), at which time the 2017 Long-Term Incentive Plan ("2017 Plan") was approved by stockholder vote. The 2017 Plan allows the Company to grant both incentive stock options (“ISOs”) and non-qualified stock options (“NSOs”) to purchase a maximum of 400,000 shares of the Company's Common Stock. Under the terms of the 2017 Plan, ISOs may only be granted to Company employees and directors, while NSOs may be granted to employees, directors, advisors, and consultants. The Company's Board of Directors (the "Board") has the authority to determine to whom options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value for an ISO or an NSO. The vesting period is normally over a period of four years from the vesting date. The contractual term of an option is no longer than 10 years. The 2017 Plan also allows the Company to issue restricted stock. As provided in the 2017 Plan, on January 1, 2022 the number of shares available for issuance was increased by 4% of the outstanding stock as of December 31, 2021, which represents an increase of 196,394 shares. As of September 30, 2022, the Company had 92,510 shares available for future issuance under the 2017 Plan. Prior to adopting the 2017 Plan, the Company did not have a formal long-term incentive stock plan. Prior to the implementation of the 2017 Plan, the Company had discretion to provide designated employees of the Company and its affiliates, certain consultants, and advisors who perform services for the Company and its affiliates, and non-employee members of the Board and its affiliates with the opportunity to receive grants of non-qualified stock options (the "Pre-2017 Non-Qualified Stock Options"). All of the Pre-2017 Non-Qualified Stock Option Grants were intended to qualify as non-qualified stock options. There were no Pre-2017 Non-Qualified Stock Option Grants that were intended to qualify as incentive stock options. On July 8, 2021, the Board of Directors of the Company adopted the 2021 Inducement Equity Incentive Plan (the “Inducement Plan”) and, subject to the adjustment provisions of the Inducement Plan, reserved 100,000 shares of the Company’s Common Stock for issuance pursuant to equity awards granted under the Inducement Plan. On December 9, 2021, the Board of Directors of the Company amended the Inducement Plan to reserve an additional 100,000 shares of the Company’s Common Stock under the Inducement Plan. As of September 30, 2022, the Compan y had 70,250 shares availa ble for grant under the 2021 Inducement Plan. Pre-2017 Non-Qualified Stock Options As of December 31, 2021, the Company had outstanding Pre-2017 Non-Qualified Stock Options to purchase, in the aggregate, 1,950,500 shares of the Company's Common Stock. During the nine months ended September 30, 2022, the Company did not grant any Pre-2017 Non-Qualified Stock Options. Stock option activity for the Pre-2017 Non-Qualified Stock Options for the nine months ended September 30, 2022 is presented in the table below: Number of Shares Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2021 1,950,500 $ 7.17 3.4 $ 51,602 Exercised — — Forfeited — — Outstanding at September 30, 2022 1,950,500 $ 7.17 2.65 $ 6,975 A summary of the status of the Company’s non-vested Pre-2017 Non-Qualified Stock Options as of September 30, 2022 is presented in the table below: Number of Options Weighted Average Grant Date Fair Value Vested at September 30, 2022 1,950,500 $ 7.17 During the nine months ended September 30, 2022 and 2021, the Company did not recognize any non-cash expense related to Pre-2017 Non-Qualified Stock Options, and there is no further compensation expense to be recognized for the Pre-2017 Non-Qualified Stock Options. The 2017 Plan During the nine months ended September 30, 2022, the Company did not grant any options under the 2017 Plan. Stock option activity for options granted under the 2017 Plan during the nine months ended September 30, 2022 is presented in the table below: Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 759,058 $ 19.61 7.31 $ 10,997 Granted — $ — Exercised (7,097) $ 12.91 Forfeited (13,146) $ 13.69 Balance at September 30, 2022 738,815 $ 19.78 6.52 $ 56 A summary of the status of the Company’s vested and non-vested options granted under the 2017 Plan as of September 30, 2022 is presented in the table below: Number of Shares Weighted Average Grant Date Fair Value per Share Vested at September 30, 2022 595,716 $ 20.23 Non-vested at September 30, 2022 143,009 $ 9.54 During the nine months ended September 30, 2022 and 2021, the Company recognized approximately $491 thousand and $1.4 million, respectively of non-cash expense related to options granted under the 2017 Plan. As of September 30, 2022, there was approximately $393 thousand of unrecognized compensation costs related to non-vested stock options that were granted under the 2017 Plan. Restricted Stock Activity The following summarizes the restricted stock activity under the Company's 2017 Plan during the nine months ended September 30, 2022: Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2021 104,416 $ 12.57 Restricted stock granted 147,475 $ 31.04 Restricted stock vested (47,123) $ 12.58 Restricted stock forfeited (6,925) $ 24.76 Restricted stock outstanding and unvested at September 30, 2022 197,843 $ 25.91 The Company has two different vesting terms for RSUs. For most grants, twenty five percent or (1/4) of the restricted stock units will vest on the one year anniversary of the vesting commencement date, and twenty-five percent or (1/4) will vest annually thereafter on the same day as the vesting commencement date, and for others approximately thirty-three percent (1/3) of the restricted stock units will vest on the one year anniversary of the vesting commencement date, and approximately thirty-three percent or (1/3) will vest annually thereafter on the same day as the vesting commencement date. During the nine months ended September 30, 2022 and 2021, the Company recognized approximately $2.3 million and $563 thousand, respectively of non-cash expense related to restricted stock units. As of September 30, 2022, there was $2.7 million of total unrecognized compensation cost related to restricted stock units. Performance Stock Unit Activity During the nine months ended September 30, 2022, the Company granted 80,735 performance stock units to certain employees. The performance stock units vest upon meeting various performance criteria established by the Compensation and Human Capital Committee of the Board of Directors. Performance stock unit activity granted under the 2017 Plan during the nine months ended September 30, 2022 is presented in the table below: Number of Shares Weighted Average Fair Value Per Share Performance stock outstanding and unvested at December 31, 2021 — $ — Performance stock granted 80,735 $ 32.85 Performance stock vested (20,185) $ 32.85 Performance stock forfeited (40,365) $ 32.85 Performance stock outstanding and unvested at September 30, 2022 20,185 $ 32.85 During the nine months ended September 30, 2022, the Company recognized approximately $1.1 million of non-cash expense related to performance stock units under the 2017 Plan. As of September 30, 2022, there was $0.4 million of total unrecognized compensation cost related to performance stock units under the 2017 Plan. Inducement Plan During the nine months ended September 30, 2022, the Company did not grant any options under the Inducement Plan. Stock option activity for options granted under the Inducement Plan during the nine months ended September 30, 2022 is presented in the table below: Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 56,500 $ 16.41 9.55 $ 973 Granted — $ — Exercised — $ — Forfeited — $ — Balance at September 30, 2022 56,500 $ 16.41 8.8 $ — During the nine months ended September 30, 2022, the Company recognized approximately $232 thousand of non-cash expense related to options granted under the Inducement Plan. As of September 30, 2022, there was approximately $205 thousand of total unrecognized compensation cost related to the non-vested stock options that were granted under the Inducement Plan. Restricted Stock Activity The following summarizes the restricted stock activity under the Inducement Plan during the nine months ended September 30, 2022: Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2021 49,800 $ 26.98 Restricted stock granted 30,450 $ 13.89 Restricted stock vested (4,550) $ 16.41 Restricted stock forfeited (5,450) $ 32.11 Restricted stock outstanding and unvested at September 30, 2022 70,250 $ 21.59 During the nine months ended September 30, 2022, the Company recognized approximately $540 thousand of non-cash expense related to restricted stock units granted under the Inducement Plan. As of September 30, 2022, there was $0.9 million of total unrecognized compensation cost related to restricted stock units granted under the Inducement Plan. Warrants During the nine months ended September 30, 2022, the Company did not issue any warrants. Warrant activity for the nine months ended September 30, 2022 is presented in the table below: Number of Shares Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2021 278,800 $ 9.72 2.51 $ 6,666 Exercised — $ — Forfeited — $ — Outstanding at September 30, 2022 278,800 $ 9.72 1.76 $ 107 Exercisable at September 30, 2022 278,800 $ 9.72 1.76 $ 107

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments The Company has entered into various agreements related to its business activities. The following is a summary of the Company’s commitments: Aptar Agreement On October 26, 2020, the Company entered into a Master Services Agreement (“MSA”) with AptarGroup, Inc. and Aptar France (collectively “Aptar”) to provide non-exclusive technology access and co-development services for the development and submission of an opioid antagonist for the treatment of opioid overdose using Aptar’s nasal Unidose device (the “UDS Device”). In addition to the cost of the UDS Devices, the Company expects to spend up to approximately $5.2 million over the course of the development program. Under the Master Service Agreement, the Company will be required to pay Aptar 750 thousand Euro upon the successful NDA filing. On June 8, 2022, the Company entered into a Capacity Investment Agreement (the "Capacity Agreement") with Aptar, whereby the Company will make non-refundable payments in the aggregate amount of 2.0 million Euros over eighteen months. In consideration of these payments, Aptar will guarantee that it has equipment installed and maintained for the future production of Aptar's unidose nasal device to meet the Company's potential commercial demand for OPNT003, nasal nalmefene. During the nine months ended September 30, 2022 the Company made the first payment of 1 million Euro to Aptar related to the Capacity Agreement. Summit Agreement On July 22, 2020, the Company entered into a Project Scope Agreement ("PSA") pursuant to a Master Services Agreement ("MSA") with Summit Biosciences, Inc. ("Summit"), to support the development and manufacture of a nasal spray device for opioid overdose, with the ability to expand to additional programs in the future. In accordance with the PSA, Summit will develop and produce certain pre-filled nasal spray products using a device previously evaluated as part of other FDA-approved nasal spray products. The Company will pay Summit estimated costs and fees up to approximately $11.0 million which includes paid deposits of approximately $1.1 million, which is included in current assets in the condensed consolidated balance sheet as of September 30, 2022. As of September 30, 2022 the Company has incurred $9.3 million of expense under PSAs related to the MSA with Summit. Torreya Agreement The Company entered into a consulting agreement with Torreya Partners LLP ("Torreya"), a financial advisory firm, under which Torreya agreed to provide certain financial advisory services. The Company is required to pay fees equivalent to 3.375% of all amounts received by the Company from net sales of NARCAN® into perpetuity. During the nine months ended September 30, 2022 and 2021, the Company rec orde d $153 thousand and $935 thousand, respectively of expense related to Torreya. Exclusive License and Collaboration Agreement On November 19, 2015, the Company entered into an exclusive license agreement and collaboration agreement (“LOI”) with a pharmaceutical company with certain desirable proprietary information. Pursuant to the agreement, the Company is obligated to issue shares of unregistered Common Stock upon the occurrence of various milestones. No shares were required to be issued under this agreement during the nine months ended September 30, 2022 and 2021. Supply Agreement On June 22, 2017, the Company entered into a license agreement (the "License Agreement") and a related supply agreement (the “Supply Agreement”) with Aegis Therapeutics LLC ("Aegis") pursuant to which the Company was granted an exclusive license (the “License”) to Aegis’ proprietary chemically synthesizable delivery enhancement and stabilization agents, including, but not limited to, Aegis’ Intravail® absorption enhancement agents, ProTek® and HydroGel® (collectively, the “Technology”) to exploit (a) the Compounds (as such are defined in the License Agreement) and (b) a product containing a Compound and formulated using the Technology (“Product”), in each case of (a) and (b) for any and all purposes. The License Agreement restricts the Company's ability to manufacture any Aegis excipients included in the Technology (“Excipients”), except for certain instances of supply failure, supply shortage or termination of the Supply Agreement, and the Company shall obtain all supply of such Excipients from Aegis under the Supply Agreement. The License Agreement also restricts Aegis’s ability to compete with the Company worldwide with respect to the Exploitation (as defined in the License Agreement) of any therapeutic containing a Compound or derivative or active metabolite of a Compound without the Company's prior written consent. The effective date of the License Agreement and the Supply Agreement is January 1, 2017. As consideration for the grant of the License, the Company paid Aegis two immaterial upfront payments, of which the Company paid 50% by issuing the Company's Common Stock to Aegis, with the number of shares issued equal to 75% of the average closing price of the Company's Common Stock over the 20 trading days preceding the date of payment. The License Agreement also provides for (A) additional developmental milestone payments for each Product containing a different Compound equal to up to an aggregate of $1.8 million, (B) additional commercialization milestone payments for each Product containing a different Compound equal to up to an aggregate of $5.0 million, and (C) single low digit royalties on the Annual Net Sales (as defined in the License Agreement) of all Products during the Royalty Term (as defined in the License Agreement) according to a tiered royalty rate based on Annual Net Sales of the Products by the Company, the Company's sublicensees and affiliates. The Company shall also pay to Aegis a sublicense fee based on a sublicense rate negotiated in good faith by the parties. The License Agreement contains customary representations and warranties, ownership, patent rights, confidentiality, indemnification and insurance provisions. The License Agreement shall expire upon the expiration of the Company's obligation to pay royalties under such License Agreement; provided, however, that the Company shall have the right to terminate the License granted on a Product-by-Product or country-by-country basis upon 30 days prior written notice to Aegis. Under the terms of the Supply Agreement, Aegis shall deliver to the Company any preclinical, clinical and commercial supply of the Excipients, which Aegis sources from various contract manufacturers. The Supply Agreement has a term of 20 years but shall terminate automatically in the event of expiration or termination of the License Agreement or at any time upon the written agreement of both parties. The Supply Agreement contains customary provisions relating to pricing for such materials, forecasts, delivery, inspection, indemnification, insurance and representations, warranties and covenants. The Supply Agreement includes technology transfer provisions for the transfer of all materials and know-how specific to the manufacturing of the Excipients that is necessary or useful for the Company to manufacture such Excipients. The Company does not have the right to manufacture such Excipients except in the event that Aegis is unable to supply and sell any portion of the material to the Company (subject to a 60-day cure period). Under the License Agreement, the Company will be required to pay Aegis $250 thousand upon the successful NDA filing. For the nine months ended September 30, 2022, and September 30, 2021, the Company did not have any expenses associated with the License Agreement. Contingencies The Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss will be incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. If any legal matter, were resolved against the Company in a reporting period for amounts in excess of management’s expectations, the Company’s would reflect any potential claim in the consolidated financial statements for that reporting period. The Company and Emergent BioSolutions Inc., through its Adapt Pharma subsidiaries (collectively, “Plaintiffs”), filed complaints, in 2016 against Teva Pharmaceuticals Industries Ltd. (“Teva”), and in 2018 against Perrigo UK FINCO Limited Partnership (“Perrigo”), relating to Teva’s and Perrigo’s respective abbreviated new drug applications (each, an “ANDA”) seeking to market generic versions of NARCAN® (naloxone hydrochloride) Nasal Spray 4mg/spray. On January 21, 2022, the Plaintiffs and Teva Canada Limited entered into a settlement agreement to resolve the ongoing litigation. Under the terms of the settlement, Teva Canada can launch a generic NARCAN® after December 15, 2023. This date can be accelerated if a third party receives approval from the Canadian Food Inspection Agency prior to this date. On February 12, 2020, Plaintiffs and Perrigo entered into a settlement agreement to resolve the ongoing litigation. Under the terms of the settlement, Perrigo has received a non-exclusive license under the Company's patents licensed to Adapt to make, have made and market its generic naloxone hydrochloride nasal spray under its own ANDA. Perrigo’s license will be effective as of January 5, 2033 or earlier under certain circumstances including circumstances related to the outcome of the current litigation against Teva or litigation against future ANDA filers. The Perrigo settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey. Closing arguments in the Teva trial were held on February 26, 2020. On June 5, 2020, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of Teva. The Company's commercial partner EBS, appealed the decision to the Court of Appeals for the Federal Circuit. On February 10, 2022, the Court of Appeals for the Federal Circuit affirmed the decision by the U.S. District Court for the District of New Jersey in favor of Teva.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the financial statements are filed for potential recognition or disclosure. Based upon this review, the Company identified the following subsequent events: Merger On November 14, 2022, the Company announced it has that entered into a definitive merger agreement under which Indivior Inc., a subsidiary of Indivior PLC, ("Indivior") will acquire the Company for an upfront consideration of $20.00 per share, in cash (approximately $145 million in the aggregate), plus up to $8.00 per share in non-tradable contingent value rights (“CVRs”) that may become payable in the event that certain net revenue milestones are achieved by OPNT003 after its approval and US commercial launch. Pursuant to the CVRs, Indivior would pay $2.00 per CVR if OPNT003 achieves the following net revenue thresholds during any period of four consecutive quarters prior to the seventh anniversary of the US commercial launch: (i) $225 million, (ii) $300 million, and (iii) $325 million. The remaining $2.00 per CVR would be paid if OPNT003 achieves net revenue of $250 million during any period of four consecutive quarters prior to the third anniversary of the US commercial launch. The maximum amount payable by Indivior should OPNT003 achieve all four CVRs would be approximately $67 million. The transaction is subject to customary closing conditions, including U.S. antitrust clearance, clearance by the Committee on Foreign Investment in the United States, resolution of any investigation by the UK antitrust authority, and receipt of approval of the Company’s stockholders. Pending approvals, the Company anticipates completing the transaction in the first quarter of 2023. The merger agreement has been unanimously approved by the board of directors of the Company. Agreement with EBS On November 13, 2022 the Company entered into an agreement with EBS, whereby the Company will receive a one-time cash payment from EBS of $25.0 million, which includes the 10% owned by SWK Holdings, LLC, and in exchange the Company will grant EBS a worldwide, sublicensable, irr evocable, perpetual, fully paid, exclusive license for NARCAN® Nasal Spray, and to the licensed patents and licensed know-how. The Company's rights under the License Agreement, dated as of December 15, 2014, and as amended from time to time, to receive any unpaid or future payments under the License Agreement, including royalties related to Net Sales of Products (as defined therein), including NARCAN® Nasal Spray, were terminated upon the effective date of this agreement. The November 13, 2022 agreement with EBS, including the payment, also resolves the Default Notice delivered by the Company to EBS on August 10, 2022. Equity

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly the Company's financial position as of September 30, 2022 and December 31, 2021, results of operations for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited, a company incorporated on November 4, 2016 under the England and Wales Companies Act of 2006. Intercompany balances and transactions are eliminated upon consolidation. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K filed with the SEC on March 15, 2022.
Use of Estimates	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of: deferred income tax assets, equity instruments, stock-based compensation, acquired intangibles, and allowances for accounts receivable.
Cash and Cash Equivalents	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents were approximately $35.4 million and $37.9 million at September 30, 2022 and December 31, 2021, respectively. The Company maintains cash balances at financial institutions insured up to $250 thousand by the Federal Deposit Insurance Corporation. Balances in the UK are insured up to £85 thousand by the Financial Services Compensation Scheme (UK Equivalent). Although the Company’s cash balances exceeded these insured amounts at various times during the nine months ended September 30, 2022, the Company has not experienced any losses on its deposits of cash and cash equivalents for the periods presented.
Earnings (Loss) Per Share	Basic and diluted earnings (loss) per share is computed by dividing loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period.     Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the respective period presented in the Company’s accompanying condensed consolidated financial statements. Fully-diluted earnings (loss) per share is computed similarly to basic income (loss) per share except that the denominator is increased to include the number of Common Stock equivalents (primarily outstanding options and warrants).
Foreign Currency Translation	The functional currency of the Company's wholly-owned subsidiary, Opiant UK is the British Pound, its local currency. Consequently, its assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of Opiant Pharmaceuticals UK Limited (“Opiant UK”), into U.S. dollars, the reporting currency, are excluded from the determination of net loss and are recorded in accumulated other comprehensive loss, a separate component of equity. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.
Recently Adopted Accounting Pronouncements	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, ("FASB"), or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.    The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its consolidated financial statements.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Earnings (Loss) Per Share, Basic and Diluted	Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the respective period presented in the Company’s accompanying condensed consolidated financial statements. Fully-diluted earnings (loss) per share is computed similarly to basic income (loss) per share except that the denominator is increased to include the number of Common Stock equivalents (primarily outstanding options and warrants). (in thousands, except per share data) For the Three Months Ended September 30, For the Nine Months Ended September 30, Numerator: 2022 2021 2022 2021 Net Income (loss) $ (9,917) $ 3,417 $ (33,841) $ 2,256 Denominator: Denominator for basic income (loss) per share - weighted average shares 5,138,274 4,462,236 5,083,222 4,359,759 Effect of dilutive securities: Equity incentive plans — 1,602,808 — 1,205,306 Denominator for diluted income (loss) per share 5,138,274 6,065,044 5,083,222 5,565,065 Income (loss) per share - Basic $ (1.93) $0.77 $ (6.66) $ 0.52 Income (loss) per share - Diluted $ (1.93) $0.56 $ (6.66) $ 0.41
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive. For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Options to purchase common stock 2,745,815 295,550 2,745,815 407,975 Warrants to purchase common stock 278,800 — 278,800 — Unvested restricted stock 268,093 — 268,093 21,425 Unvested performance stock 20,185 — 20,185 — Shares issuable upon conversion of convertible debt 222,332 509,165 222,332 509,165 Total 3,535,225 804,715 3,535,225 938,565

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Summary of Operating Leases	The following table summarizes information related to the Company's operating leases and are included in the Company's Balance Sheet as of September 30, 2022. Balance Sheet descriptions September 30, 2022 Assets: (in thousands) Right of use assets - operating leases $ 2,739 Liabilities: Operating leases - current 669 Operating leases - long term 2,084 Total lease liabilities: $ 2,753
Summary of Components of Operating Lease Cost	The following table summarizes the components of operating lease cost for the three and nine months ended September 30, 2022: Lease costs, (in thousands) Three months ended September 30, 2022 Nine months ended September 30, 2022 Operating expenses lease costs $ 149 $ 395
Maturity of Operating Lease Liabilities	As of September 30, 2022, future minimum operating leases payments related to the Company’s operating lease liabilities were as follows: (in thousands) September 30, 2022 2022 (three months remaining) $ 179 2023 709 2024 737 2025 780 2026 and thereafter 1,036 Total lease payments 3,441 Less imputed interest (688) Present value of operating lease liabilities $ 2,753

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue Recognition [Abstract]
Schedule of Deferred Revenue Activity	The following is a summary of the Company’s deferred revenue activity as of September 30, 2022: (in thousands) NIDA Grant Total Balance as of December 31, 2021 $ 17 $ 17 Additions to deferred revenue — — Recognized as revenue (17) (17) Balance as of September 30, 2022 $ — $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Share-based Compensation, Stock Options, Activity	Stock option activity for the Pre-2017 Non-Qualified Stock Options for the nine months ended September 30, 2022 is presented in the table below: Number of Shares Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2021 1,950,500 $ 7.17 3.4 $ 51,602 Exercised — — Forfeited — — Outstanding at September 30, 2022 1,950,500 $ 7.17 2.65 $ 6,975 Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 759,058 $ 19.61 7.31 $ 10,997 Granted — $ — Exercised (7,097) $ 12.91 Forfeited (13,146) $ 13.69 Balance at September 30, 2022 738,815 $ 19.78 6.52 $ 56 Stock option activity for options granted under the Inducement Plan during the nine months ended September 30, 2022 is presented in the table below: Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 56,500 $ 16.41 9.55 $ 973 Granted — $ — Exercised — $ — Forfeited — $ — Balance at September 30, 2022 56,500 $ 16.41 8.8 $ — Warrant activity for the nine months ended September 30, 2022 is presented in the table below: Number of Shares Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2021 278,800 $ 9.72 2.51 $ 6,666 Exercised — $ — Forfeited — $ — Outstanding at September 30, 2022 278,800 $ 9.72 1.76 $ 107 Exercisable at September 30, 2022 278,800 $ 9.72 1.76 $ 107
Schedule of Nonvested Share Activity	A summary of the status of the Company’s non-vested Pre-2017 Non-Qualified Stock Options as of September 30, 2022 is presented in the table below: Number of Options Weighted Average Grant Date Fair Value Vested at September 30, 2022 1,950,500 $ 7.17 A summary of the status of the Company’s vested and non-vested options granted under the 2017 Plan as of September 30, 2022 is presented in the table below: Number of Shares Weighted Average Grant Date Fair Value per Share Vested at September 30, 2022 595,716 $ 20.23 Non-vested at September 30, 2022 143,009 $ 9.54
Restricted Stock Activity	The following summarizes the restricted stock activity under the Company's 2017 Plan during the nine months ended September 30, 2022: Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2021 104,416 $ 12.57 Restricted stock granted 147,475 $ 31.04 Restricted stock vested (47,123) $ 12.58 Restricted stock forfeited (6,925) $ 24.76 Restricted stock outstanding and unvested at September 30, 2022 197,843 $ 25.91 Number of Shares Weighted Average Fair Value Per Share Performance stock outstanding and unvested at December 31, 2021 — $ — Performance stock granted 80,735 $ 32.85 Performance stock vested (20,185) $ 32.85 Performance stock forfeited (40,365) $ 32.85 Performance stock outstanding and unvested at September 30, 2022 20,185 $ 32.85 Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2021 49,800 $ 26.98 Restricted stock granted 30,450 $ 13.89 Restricted stock vested (4,550) $ 16.41 Restricted stock forfeited (5,450) $ 32.11 Restricted stock outstanding and unvested at September 30, 2022 70,250 $ 21.59

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 GBP (£)	Dec. 31, 2021 USD ($)
Accounting Policies [Abstract]
Cash and cash equivalents	$ 35,375,865		$ 37,853,947
FDIC insured amount	$ 250,000
FSCS insured amount | £		£ 85,000

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Earnings (Loss) Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net (loss) income	$ (9,916,639)	$ (11,736,546)	$ (12,187,830)	$ 3,417,099	$ 1,683,591	$ (2,844,230)	$ (33,841,015)	$ 2,256,460
Denominator:
Denominator for basic income (loss) per share - weighted-average shares (in shares)	5,138,274			4,462,236			5,083,222	4,359,759
Equity incentive plans (in shares)	0			1,602,808			0	1,205,306
Denominator for diluted income (loss) per share (in shares)	5,138,274			6,065,044			5,083,222	5,565,065
Income (loss) per share - basic (in dollars per share)	$ (1.93)			$ 0.77			$ (6.66)	$ 0.52
Income (loss) per share - diluted (in dollars per share)	$ (1.93)			$ 0.56			$ (6.66)	$ 0.41

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	3,535,225	804,715	3,535,225	938,565
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	2,745,815	295,550	2,745,815	407,975
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	278,800	0	278,800	0
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	268,093	0	268,093	21,425
Unvested performance stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	20,185	0	20,185	0
Shares issuable upon conversion of convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	222,332	509,165	222,332	509,165

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 41,113	$ 13,327,364
BARDA
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 41,000
Royalty revenue from sales of NARCAN
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable		$ 13,300,000

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid and other current assets	$ 3,131,299	$ 2,962,903

Leases - Narrative (Details)

Leases - Narrative (Details)	9 Months Ended
	Sep. 30, 2022 lease
Leases [Abstract]
Number of operating leases	2
Renewal term	5 years
Operating lease, weighted average discount rate, percent	8.80%
Operating lease, weighted average remaining lease term	4 years 7 months 6 days

Leases - Balance Sheet Descript

Leases - Balance Sheet Descriptions of Operating Leases (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Assets:
Right of use assets - operating leases	$ 2,739,239	$ 999,567
Liabilities:
Operating leases - current	669,209	337,690
Operating leases - long term	2,083,548	$ 673,347
Total lease liabilities:	$ 2,753,000

Leases - Components of Operatin

Leases - Components of Operating Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Leases [Abstract]
Operating expenses lease costs	$ 149	$ 395

Leases - Maturity of Operating

Leases - Maturity of Operating Lease Liabilities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Leases [Abstract]
2022 (three months remaining)	$ 179
2023	709
2024	737
2025	780
2026 and thereafter	1,036
Total lease payments	3,441
Less imputed interest	(688)
Present value of operating lease liabilities	$ 2,753

Other Non-Current Assets (Detai

Other Non-Current Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other non-current assets	$ 234,389	$ 179,532

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($)			3 Months Ended		9 Months Ended		48 Months Ended
	Mar. 31, 2022	Sep. 19, 2018	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Apr. 17, 2018
Deferred Revenue Arrangement [Line Items]
Revenue			$ 0	$ 14,041,006	$ 4,519,505	$ 27,688,713
Grant and contract revenue			173,874	$ 2,298,055	4,018,653	$ 6,296,542
Grants receivable								$ 7,400,000
Recognized as revenue					17,000
BARDA
Deferred Revenue Arrangement [Line Items]
Proceeds from funding agreement							$ 10,800,000
Grant and contract revenue			200,000		4,000,000
Grant
Deferred Revenue Arrangement [Line Items]
Revenue	$ 7,400,000
NIDA Grant
Deferred Revenue Arrangement [Line Items]
Recognized as revenue			$ 0		$ 17,000
Plan | BARDA
Deferred Revenue Arrangement [Line Items]
Proceeds from funding agreement		$ 10,800,000

Revenue - Summary of Deferred R

Revenue - Summary of Deferred Revenue Activity (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Movement in Deferred Revenue [Roll Forward]
Balance at beginning of period		$ 17
Additions to deferred revenue		0
Recognized as revenue		(17)
Balance at end of period	$ 0	0
NIDA Grant
Movement in Deferred Revenue [Roll Forward]
Balance at beginning of period		17
Additions to deferred revenue		0
Recognized as revenue	0	(17)
Balance at end of period	$ 0	$ 0

Royalty Payable (Details)

Royalty Payable (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Royalty payable	$ 0	$ 2,920,148

Debt (Details)

Debt (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Short term and long term debt	$ 13,800,000
Long term debt	12,324,237	$ 16,069,085
Debt conversion, original debt, amount	$ 2,600,000
Debt instrument, convertible, conversion price( in dollar per share)	$ 19.64

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($) $ in Thousands	3 Months Ended					9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from stock option and warrant exercises						$ 92
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)	37,826	7,410				7,097
Restricted stock issued (in shares)	4,550	15,375	31,746	13,375	6,527	51,671
Performance stock units issued (in shares)		20,185				20,185
Common stock | Controlled Equity Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock number of shares (in shares)						45,236
Sale of stock, consideration received on transaction						$ 538

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options (Details) - shares			9 Months Ended
	Jan. 01, 2022	Dec. 09, 2021	Sep. 30, 2022	Jul. 08, 2021	Sep. 08, 2017
2021 Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares authorized (in shares)				100,000
Annual additional options authorized (in shares)		100,000
Shares available for future issuance (in shares)			70,250
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage increase of authorized shares	4%
Annual additional options authorized (in shares)	196,394
Options to purchase common stock | 2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares authorized (in shares)					400,000
Expiration period			10 years
Shares available for future issuance (in shares)			92,510
Options to purchase common stock | 2017 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			4 years

Stockholders' Equity - Pre-2017

Stockholders' Equity - Pre-2017 Non-Qualified Stock Options, Additional Information (Details) - Pre-2017 non-qualified stock options - shares	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	1,950,500	1,950,500
Granted (in shares)	0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Pre-2017 Non-Qualified Stock Options Outstanding (Details) - Pre-2017 non-qualified stock options - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Number of Shares
Outstanding at beginning of period (in shares)	1,950,500
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding at end of period (in shares)	1,950,500	1,950,500
Weighted-average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 7.17
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	0
Outstanding at end of period (in dollars per share)	$ 7.17	$ 7.17
Weighted-average Remaining Contractual Term (years)
Outstanding	2 years 7 months 24 days	3 years 4 months 24 days
Aggregate Intrinsic Value
Outstanding	$ 6,975	$ 51,602

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Pre-2017 Non-Qualified Stock Options Nonvested Share Activity (Details) - Pre-2017 non-qualified stock options	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of Shares
Vested (in shares) | shares	1,950,500
Weighted Average Grant Date Fair Value
Vested (in dollars per share) | $ / shares	$ 7.17

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of 2017 Plan Options Outstanding (Details) - 2017 Plan - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Number of Options Outstanding
Outstanding at beginning of period (in shares)	759,058
Granted (in shares)	0
Exercised (in shares)	(7,097)
Forfeited (in shares)	(13,146)
Outstanding at end of period (in shares)	738,815	759,058
Weighted-average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 19.61
Granted (in dollars per share)	0
Exercised (in dollars per share)	12.91
Forfeited (in dollars per share)	13.69
Outstanding at end of period (in dollars per share)	$ 19.78	$ 19.61
Weighted-average Remaining Contractual Term (years)
Outstanding	6 years 6 months 7 days	7 years 3 months 21 days
Aggregate Intrinsic Value
Outstanding	$ 56	$ 10,997

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of 2017 Nonvested Share Activity (Details) - 2017 Plan	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of Shares
Vested (in shares) | shares	595,716
Non-vested, ending balance (in shares) | shares	143,009
Weighted Average Grant Date Fair Value
Vested (in dollars per share) | $ / shares	$ 20.23
Non-vested, ending balance (in dollars per share) | $ / shares	$ 9.54

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of 2017 Plan (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 2,300	$ 563
2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation not yet recognized	393
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	232
Options to purchase common stock | 2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 491	$ 1,400

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Weighted Average Fair Value Per Share
Stock based compensation expense	$ 2,300	$ 563
Compensation cost not yet recognized	$ 2,700
Unvested restricted stock
Number of Shares
Outstanding at beginning of period (in shares)	104,416
Granted (in shares)	147,475
Vested (in shares)	(47,123)
Forfeited (in shares)	(6,925)
Outstanding at end of period (in shares)	197,843
Weighted Average Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 12.57
Granted (in dollars per share)	31.04
Vested (in dollars per share)	12.58
Forfeited (in dollars per share)	24.76
Outstanding at end of period (in dollars per share)	$ 25.91
Options to purchase common stock
Weighted Average Fair Value Per Share
Stock based compensation expense	$ 232
Compensation cost not yet recognized	205
Options to purchase common stock | 2017 Plan
Weighted Average Fair Value Per Share
Stock based compensation expense	$ 491	$ 1,400
Options to purchase common stock | 2017 Plan | Tranche One
Weighted Average Fair Value Per Share
Vesting percentage	25%
Options to purchase common stock | 2017 Plan | Tranche Two
Weighted Average Fair Value Per Share
Vesting percentage	25%
Options to purchase common stock | 2017 Plan | Tranche Three
Weighted Average Fair Value Per Share
Vesting percentage	25%
Options to purchase common stock | 2017 Plan | Tranche Four
Weighted Average Fair Value Per Share
Vesting percentage	33%

Stockholders' Equity - Performa

Stockholders' Equity - Performance Stock Unit Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Weighted Average Fair Value Per Share
Stock based compensation expense	$ 2,300	$ 563
Compensation cost not yet recognized	$ 2,700
Unvested performance stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	80,735
Number of Shares
Outstanding at beginning of period (in shares)	0
Granted (in shares)	80,735
Vested (in shares)	(20,185)
Forfeited (in shares)	(40,365)
Outstanding at end of period (in shares)	20,185
Weighted Average Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 0
Granted (in dollars per share)	32.85
Vested (in dollars per share)	32.85
Forfeited (in dollars per share)	32.85
Outstanding at end of period (in dollars per share)	$ 32.85
Stock based compensation expense	$ 1,100
Compensation cost not yet recognized	$ 400

Stockholders' Equity - Induceme

Stockholders' Equity - Inducement Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Aggregate Intrinsic Value
Stock based compensation expense	$ 2,300	$ 563
Compensation cost not yet recognized	2,700
Options to purchase common stock
Aggregate Intrinsic Value
Stock based compensation expense	232
Compensation cost not yet recognized	$ 205
Inducement Equity Incentive Plan
Number of Shares
Outstanding at beginning of period (in shares)	56,500
Granted (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding at end of period (in shares)	56,500		56,500
Weighted-average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 16.41
Granted (in dollars per share)	0
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	0
Outstanding at end of period (in dollars per share)	$ 16.41		$ 16.41
Weighted-average Remaining Contractual Term (years)
Outstanding	8 years 9 months 18 days		9 years 6 months 18 days
Aggregate Intrinsic Value
Outstanding	$ 0		$ 973

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Restricted Stock Units Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Weighted Average Fair Value Per Share
Stock based compensation expense	$ 2,300	$ 563
Compensation cost not yet recognized	$ 2,700
Unvested restricted stock
Number of Shares
Outstanding at beginning of period (in shares)	104,416
Granted (in shares)	147,475
Vested (in shares)	(47,123)
Forfeited (in shares)	(6,925)
Outstanding at end of period (in shares)	197,843
Weighted Average Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 12.57
Granted (in dollars per share)	31.04
Vested (in dollars per share)	12.58
Forfeited (in dollars per share)	24.76
Outstanding at end of period (in dollars per share)	$ 25.91
Unvested restricted stock | Inducement Equity Incentive Plan
Number of Shares
Outstanding at beginning of period (in shares)	49,800
Granted (in shares)	30,450
Vested (in shares)	(4,550)
Forfeited (in shares)	(5,450)
Outstanding at end of period (in shares)	70,250
Weighted Average Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 26.98
Granted (in dollars per share)	13.89
Vested (in dollars per share)	16.41
Forfeited (in dollars per share)	32.11
Outstanding at end of period (in dollars per share)	$ 21.59
Restricted Stock Units | Inducement Equity Incentive Plan
Weighted Average Fair Value Per Share
Stock based compensation expense	$ 540
Compensation cost not yet recognized	$ 900

Stockholders' Equity - Schedu_7

Stockholders' Equity - Schedule of Warrants Outstanding (Details) - Warrants to purchase common stock - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Number of Shares
Outstanding at beginning of period (in shares)	278,800
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding at end of period (in shares)	278,800	278,800
Exercisable (in shares)	278,800
Weighted Average Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 9.72
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	0
Outstanding at end of period (in dollars per share)	9.72	$ 9.72
Exercisable (in dollars per share)	$ 9.72
Weighted-average Remaining Contractual Term (years)
Outstanding	1 year 9 months 3 days	2 years 6 months 3 days
Exercisable weighted average remaining contractual terms	1 year 9 months 3 days
Aggregate Intrinsic Value
Outstanding	$ 107	$ 6,666
Exercisable aggregate intrinsic value	$ 107

Commitments and Contingencies -

Commitments and Contingencies - Aptar Agreement (Details) - AptarGroup, Inc. $ in Thousands, € in Millions			9 Months Ended
	Jun. 08, 2022 EUR (€)	Oct. 26, 2020 USD ($)	Sep. 30, 2022 EUR (€)
Other Commitments [Line Items]
Development costs | $		$ 5,200
Payments for development costs | $		$ 750
Capacity investment agreement
Other Commitments [Line Items]
Other commitment | €	€ 2
Other commitment over the period	18 months
Payments for other commitments | €			€ 1

Commitments and Contingencies_2

Commitments and Contingencies - Summit Agreement (Details) - Summit BioScience, Inc. - USD ($) $ in Millions	Jul. 22, 2020	Sep. 30, 2022
Other Commitments [Line Items]
Estimated fees and cost (up to)	$ 11
Payment for deposit	$ 1.1
Agreement expense accrual		$ 9.3

Commitments and Contingencies_3

Commitments and Contingencies - Torreya Agreement (Details) - Advisory services - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Other Commitments [Line Items]
Additional consultant fee payable, percentage of perpetuity	3.375%
Sponsor fees	$ 153	$ 935

Commitments and Contingencies_4

Commitments and Contingencies - Exclusive License and Collaboration Agreement (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Letter of intent
Other Commitments [Line Items]
Stock newly-issued during the period (in shares)	0	0

Commitments and Contingencies_5

Commitments and Contingencies - Supply Agreement (Details) $ in Thousands	Jun. 22, 2017 USD ($) payment day	Sep. 30, 2022 USD ($)
License agreement
Other Commitments [Line Items]
Upfront payments | payment	2
Percent of upfront payments which may be paid by issuing common stock	50%
Percent of average share price	75%
Threshold trading days | day	20
Maximum additional product milestone payments	$ 1,800
Maximum additional commercialization milestone payments	$ 5,000
Termination advance notice period	30 days
Other commitment		$ 250
Supply agreement
Other Commitments [Line Items]
Other commitment, period	20 years
Material cure period	60 days

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	9 Months Ended
	Nov. 14, 2022	Oct. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Total contract amount			$ 0	$ 17
Restricted stock
Subsequent Event [Line Items]
Granted (in shares)			147,475
Subsequent event | 2017 Long Term Incentive Plan | Restricted stock
Subsequent Event [Line Items]
Granted (in shares)		4,900
Subsequent event | Royalty revenue from sales of NARCAN
Subsequent Event [Line Items]
Total contract amount	$ 25,000
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC.
Subsequent Event [Line Items]
Share price (in dollars per share)	$ 20
Cash consideration	$ 145,000
Share price, CVR (in dollars per share)	$ 8
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Rights
Subsequent Event [Line Items]
CVR liability, maximum amount	$ 67,000
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Right, Scenario 1
Subsequent Event [Line Items]
Share price, CVR (in dollars per share)	$ 2
CVR liability	$ 225,000
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Right, Scenario 2
Subsequent Event [Line Items]
Share price, CVR (in dollars per share)	$ 2
CVR liability	$ 300,000
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Right, Scenario 3
Subsequent Event [Line Items]
Share price, CVR (in dollars per share)	$ 2
CVR liability	$ 325,000
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Right, Scenario 4
Subsequent Event [Line Items]
Share price, CVR (in dollars per share)	$ 2
CVR liability	$ 250,000